News
FDA approves Moderna COVID vaccine for kids under 12 at higher risk
Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its Spikevax (mRNA-1273) COVID vaccine for children 6 months to 11 years old. But, because federal officials in May restricted its recommendations for COVID-19 vaccines to adults 65 and older and to people of all ages who are at increased risk for severe disease,
Moderna's new COVID-19 vaccine mNexspike approved by FDA, but there's a limit on who can use it. May 31, 2025 / 4:41 PM EDT / CBS/AP Experts warn about COVID-19 guidelines .
mNEXSPIKE becomes Moderna's third FDA-approved product. CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration ...
Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64. advertisement. Barron's. Moderna Stock Is Rising.
Moderna says it plans to offer both the mNexspike and its already approved vaccine starting in the fall. The original shot remains available for people ages 6 months and older. 5.
FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations: Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE (mRNA-1283), has received FDA approval for adults aged 65 years and older and ...
The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.. The new vaccine is indicated for active immunization to prevent COVID-19 caused ...
The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 4 The FDA has approved Moderna’s next-generation COVID-19 vaccine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback